Drug Information

Drug (ID: DG00010) and It's Reported Resistant Information

• Name: Baicalein
• Synonyms: Baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Noroxylin; Biacalein; BaiKalein; Baicelein; UNII-49QAH60606; NSC661431; NSC 661431; CHEMBL8260; 5,6,7-trihydroxy-2-phenylchromen-4-one; CHEBI:2979; FXNFHKRTJBSTCS-UHFFFAOYSA-N; MFCD00017459; 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl-; 49QAH60606; 5,7-Trihydroxyflavone; 5,6,7-trihydroxy-2-phenyl-chromen-4-one; Sho-saiko-to; SMR000112462; SR-01000597499; Baicalein, 8; Baicalein,(S); 3WL; Baicalein, 14; Baicalein, 98%; AC1NQYPP; Tocris-1761
• Indication:
  In total 1 Indication(s)
  Influenza [ICD-11: 1E30]; Phase 2; [1]
• Target: Arachidonate 5-lipoxygenase (5-LOX); LOX5_HUMAN; [1]
• Target: L-selectin (SELL); LYAM1_HUMAN; [1]
• Target: Lactoylglutathione lyase (GLO1); LGUL_HUMAN; [1]
• Target: P-selectin (SELP); LYAM3_HUMAN; [1]
• Target: Prolyl endopeptidase (PREP); PPCE_HUMAN; [1]
• Target: Tumor necrosis factor (TNF); TNFA_HUMAN; [1]
• Target: Xanthine dehydrogenase/oxidase (XDH); XDH_HUMAN; [1]
• Formula: C15H10O5
• IsoSMILES: C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O
• InChI: 1S/C15H10O5/c16-9-6-11(8-4-2-1-3-5-8)20-12-7-10(17)14(18)15(19)13(9)12/h1-7,17-19H
• InChIKey: FXNFHKRTJBSTCS-UHFFFAOYSA-N
• PubChem CID: 5281605
• ChEBI ID: CHEBI:2979
• TTD Drug ID: D00YEV
• DrugBank ID: DB16101

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Liver cancer [ICD-11: 2C12]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: NF-kappaB interacting LncRNA (NKILA) [2]

• Molecule Alteration: Expression; Up-regulation
• Sensitive Disease: Hepatocellular carcinoma [ICD-11: 2C12.2]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell apoptosis; Activation; hsa04210
• Cell Pathway Regulation: Cell invasion; Inhibition; hsa05200
• Cell Pathway Regulation: Cell viability; Inhibition; hsa05200
• Cell Pathway Regulation: NF-kappaB signaling pathway; Inhibition; hsa04064
• In Vitro Model: HepG2 cells; Liver; Homo sapiens (Human); CVCL_0027
• In Vitro Model: HCCLM3 cells; Liver; Homo sapiens (Human); CVCL_6832
• In Vitro Model: Hep3B cells; Liver; Homo sapiens (Human); CVCL_0326
• In Vitro Model: SMMC7721 cells; Uterus; Homo sapiens (Human); CVCL_0534
• In Vitro Model: QSG-7701 cells; Liver; Homo sapiens (Human); CVCL_6944
• In Vivo Model: Nude mouse xenograft model; Mus musculus
• Experiment for Molecule Alteration: qRT-PCR
• Experiment for Drug Resistance: Luminescent cell viability assay; TUNEL assay; Transwell assay
• Mechanism Description: NkILA inhibited IkBalpha phosphorylation and enhanced the inhibitory roles of baicalein on NF-kB signaling in HCC cells.

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: NF-kappa-B inhibitor alpha (NFKBIA) [2]

• Molecule Alteration: Phosphorylation; Down-regulation
• Sensitive Disease: Hepatocellular carcinoma [ICD-11: 2C12.2]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell apoptosis; Activation; hsa04210
• Cell Pathway Regulation: Cell invasion; Inhibition; hsa05200
• Cell Pathway Regulation: Cell viability; Inhibition; hsa05200
• Cell Pathway Regulation: NF-kappaB signaling pathway; Inhibition; hsa04064
• In Vitro Model: HepG2 cells; Liver; Homo sapiens (Human); CVCL_0027
• In Vitro Model: HCCLM3 cells; Liver; Homo sapiens (Human); CVCL_6832
• In Vitro Model: Hep3B cells; Liver; Homo sapiens (Human); CVCL_0326
• In Vitro Model: SMMC7721 cells; Uterus; Homo sapiens (Human); CVCL_0534
• In Vitro Model: QSG-7701 cells; Liver; Homo sapiens (Human); CVCL_6944
• In Vivo Model: Nude mouse xenograft model; Mus musculus
• Experiment for Molecule Alteration: Western blot analysis
• Experiment for Drug Resistance: Luminescent cell viability assay; TUNEL assay; Transwell assay
• Mechanism Description: NkILA inhibited IkBalpha phosphorylation and enhanced the inhibitory roles of baicalein on NF-kB signaling in HCC cells.

Cervical cancer [ICD-11: 2C77]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Long non-protein coding RNA (BDLNR) [1]

• Molecule Alteration: Expression; Up-regulation
• Sensitive Disease: Cervical cancer [ICD-11: 2C77.0]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: PI3K/AKT signaling pathway; Inhibition; hsa04151
• In Vitro Model: Hela cells; Cervix uteri; Homo sapiens (Human); CVCL_0030
• In Vitro Model: Siha cells; Cervix uteri; Homo sapiens (Human); CVCL_0032
• In Vitro Model: Caski cells; Uterus; Homo sapiens (Human); CVCL_1100
• In Vitro Model: ME-180 cells; Uterus; Homo sapiens (Human); CVCL_1401
• Experiment for Molecule Alteration: qRT-PCR
• Experiment for Drug Resistance: Glo cell viability assays
• Mechanism Description: Baicalein inhibits cervical cancer progression via downregulating long noncoding RNA BDLNR and its downstream PI3 k/Akt pathway. BDLNR physically bound to YBX1, recruited YBX1 to PIk3CA promoter, activated PIk3CA expression and PI3 k/Akt pathway.

References

• Ref 1: Baicalein inhibits cervical cancer progression via downregulating long noncoding RNA BDLNR and its downstream PI3K/Akt pathway. Int J Biochem Cell Biol. 2018 Jan;94:107-118. doi: 10.1016/j.biocel.2017.11.009. Epub 2017 Nov 23.
• Ref 2: Long noncoding RNA NKILA enhances the anti-cancer effects of baicalein in hepatocellular carcinoma via the regulation of NF-kB signaling. Chem Biol Interact. 2018 Apr 1;285:48-58. doi: 10.1016/j.cbi.2018.02.027. Epub 2018 Feb 23.